Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigecycline vs Imipenem/Cilastatin in Complicated Intra-abdominal Infections
NCT01721408Phase 4Completed
- Sponsor
- Pfizer
- Start
- Nov 2012
- Primary completion
- Oct 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tigecycline in Intra-abdominal infection (IAI) (2 arms), sponsored by Pfizer. Primary endpoints: Clinical Response at the Test-of-Cure (TOC) Assessment Within the Clinically Evaluable (CE) Population and Clinical Response at the TOC Assessment Within the Modified Intent-to-Treat (mITT) Population. Started Nov 2012; status: completed.
02
Drugs
tigecycline
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT01721408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01721408.